Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, Ohio.
Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Surg Obes Relat Dis. 2018 Nov;14(11):1725-1731. doi: 10.1016/j.soard.2018.07.028. Epub 2018 Aug 18.
Uncontrolled hyperglycemia in patients undergoing surgery has been shown to be a risk factor for postoperative complications.
To assess the clinical significance of perioperative hyperglycemia on infectious complications and clinical outcomes in patients undergoing bariatric surgery.
Single academic center.
Retrospective chart review of all patients who underwent primary laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy between 2013 and 2016 was performed. The association between any elevated perioperative glucose value (hyperglycemia: ≥126 mg/dL) and level of elevation (≥126 or ≥200 mg/dL) with 30-day infectious complications, reoperation, length of hospital stay, and readmission was assessed. Patients who developed early complications (within 3 d of surgery), which could potentially lead to immediate postoperative hyperglycemia, were not included in the analysis. Outcomes of patients with and without diabetes were separately analyzed.
A cohort of 1981 patients was studied, including Roux-en-Y gastric bypass (n = 1171, 59%) and sleeve gastrectomy (n = 810, 41%) patients. In patients with diabetes (n = 751, 38%), perioperative hyperglycemia was independently associated with higher composite infectious complications (defined as presence of any of 6 infectious complications; odds ratio [OR] 3.1, 95% confidence interval [CI] 1.2-8.2, P = .018) and higher readmission rate (OR 2.2, 95% CI 1.1-4.6, P = .027). In patients without diabetes (n = 1230, 62%), 19.2% had perioperative hyperglycemia (≥126 mg/dL). Perioperative hyperglycemia in patients without diabetes was associated with higher composite infectious complications (OR 2.6, 95% CI 1.1-5.5, P = .018) and prolonged length of stay (OR 3.0, 95% CI 1.5-5.9, P = .001).
An elevated perioperative glucose value is adversely associated with infectious complications and key clinical outcomes after bariatric surgery. The increased risk is correlated with the extent of glucose elevation (dose-response relationship). Our findings highlight the importance of glucose control during the perioperative period in bariatric surgical patients.
手术患者的血糖控制不佳已被证实是术后并发症的危险因素。
评估围手术期高血糖对减重手术患者感染并发症和临床结局的临床意义。
单家学术中心。
对 2013 年至 2016 年间接受腹腔镜 Roux-en-Y 胃旁路术或袖状胃切除术的所有患者进行了回顾性图表审查。评估任何升高的围手术期血糖值(高血糖:≥126mg/dL)及其升高程度(≥126 或≥200mg/dL)与 30 天内感染并发症、再次手术、住院时间和再入院之间的关系。未将发生早期并发症(术后 3 天内)的患者纳入分析,这些并发症可能导致术后即刻高血糖。分别分析了有糖尿病和无糖尿病患者的结果。
共纳入 1981 例患者,其中 Roux-en-Y 胃旁路术(n=1171,59%)和袖状胃切除术(n=810,41%)患者。在糖尿病患者(n=751,38%)中,围手术期高血糖与复合感染并发症(定义为存在任何 6 种感染并发症之一;比值比[OR]3.1,95%置信区间[CI]1.2-8.2,P=0.018)和更高的再入院率(OR 2.2,95%CI 1.1-4.6,P=0.027)独立相关。在无糖尿病患者(n=1230,62%)中,有 19.2%的患者围手术期高血糖(≥126mg/dL)。无糖尿病患者的围手术期高血糖与复合感染并发症(OR 2.6,95%CI 1.1-5.5,P=0.018)和住院时间延长(OR 3.0,95%CI 1.5-5.9,P=0.001)相关。
升高的围手术期血糖值与减重手术后的感染并发症和关键临床结局不良相关。风险增加与血糖升高的程度相关(剂量反应关系)。我们的研究结果强调了在减重手术患者围手术期控制血糖的重要性。